TP53 and ovarian serous cystadenocarcinoma: We thus evaluated associations between PDSs and drug sensitivity in five cancer types for which we could confidently capture p53 deficiency (breast invasive carcinoma, colon adenocarcinoma, ovarian serous cystadenocarcinoma, pancreatic adenocarcinoma, and skin cutaneous melanoma).